Literature DB >> 15579987

Intravitreal concentration and clearance of triamcinolone acetonide in nonvitrectomized human eyes.

John O Mason1, Mamta D Somaiya, Ravinder J Singh.   

Abstract

PURPOSE: To determine the intravitreal concentration and clearance of triamcinolone acetonide at various intervals after intravitreal injection into nonvitrectomized eyes.
METHODS: Six participants were administered 4 mg (0.1 cc) of triamcinolone acetonide ophthalmic suspension. All six eyes underwent therapeutic pars plana vitrectomy with membranectomy at various post injection intervals ranging from 1.25 to 5 months from the intravitreal injection. Undiluted specimens of vitreous overlying the macula and of aqueous humor were submitted for analysis. Vitreous and aqueous humor concentrations of triamcinolone were measured by high performance liquid chromatography.
RESULTS: Four eyes demonstrated detectable intravitreal concentrations of triamcinolone acetonide between 1.25 and 2.75 months after a single injection. Two eyes had an undetectable level of triamcinolone in both the vitreous and aqueous at 3 and 5 months post single injection.
CONCLUSIONS: The intravitreal concentration of triamcinolone acetonide is detectable up to 2.75 months post a single 4 mg injection in nonvitrectomized eyes. A reinjection interval of 3 months may be needed to achieve sustained measurable levels of triamcinolone in nonvitrectomized patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579987     DOI: 10.1097/00006982-200412000-00009

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  20 in total

1.  Influence of different purification techniques on triamcinolone yield and particle size spectrum.

Authors:  Peter Szurman; Radoslaw Kaczmarek; Gesine B Jaissle; Salvatore Grisanti; Matthias Lüke; Martin S Spitzer; Peter-Edgar Heide; Karl U Bartz-Schmidt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-09-28       Impact factor: 3.117

2.  Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy.

Authors:  M Elizabeth Hartnett; David J Martiniuk; Yuta Saito; Pete Geisen; Lynda J Peterson; Janet R McColm
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-11       Impact factor: 4.799

Review 3.  Treatment of Diabetic Macular Edema.

Authors:  Eric J Kim; Weijie V Lin; Sean M Rodriguez; Ariel Chen; Asad Loya; Christina Y Weng
Journal:  Curr Diab Rep       Date:  2019-07-29       Impact factor: 4.810

4.  [Intravitreal triamcinolone acetonide Complication of infectious and sterile endophthalmitis].

Authors:  I Kreissig; R F Degenring; J B Jonas
Journal:  Ophthalmologe       Date:  2006-01       Impact factor: 1.059

5.  Development of ocular hypertension and persistent glaucoma after intravitreal injection of triamcinolone.

Authors:  M Selim Kocabora; Cemil Yilmazli; Muhittin Taskapili; Gokhan Gulkilik; Sahan Durmaz
Journal:  Clin Ophthalmol       Date:  2008-03

6.  Intracameral dexamethasone reduces inflammation on the first postoperative day after cataract surgery in eyes with and without glaucoma.

Authors:  Diane T W Chang; Michael C Herceg; Richard A Bilonick; Larissa Camejo; Joel S Schuman; Robert J Noecker
Journal:  Clin Ophthalmol       Date:  2009-06-02

7.  Pharmacokinetic behavior of intravitreal triamcinolone acetonide prepared by a hospital pharmacy.

Authors:  Masako Oishi; Shinichiro Maeda; Noriyasu Hashida; Nobuyuki Ohguro; Yasuo Tano; Nobuo Kurokawa
Journal:  Jpn J Ophthalmol       Date:  2008-12-17       Impact factor: 2.447

8.  Unilateral choroidal granulomas complicated by choroidal neovascular membrane treated successfully with intravitreal triamcinolone in a patient with sarcoidosis.

Authors:  Tasneem Khatib; Patrick W Hughes; Benjamin J L Burton
Journal:  BMJ Case Rep       Date:  2014-08-28

9.  Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole.

Authors:  Aqeela Afzal; Sergio Caballero; Stela S Palii; Simona Jurczyk; Machelle Pardue; Dale Geroski; Henry Edelhauser; Guenther Hochhaus; Moon Kim; Alan Franklin; Gideon Shapiro; Maria B Grant
Journal:  Brain Res Bull       Date:  2009-08-11       Impact factor: 4.077

10.  Intravitreal Corticosteroids in the Management of Diabetic Macular Edema.

Authors:  Stephen G Schwartz; Harry W Flynn; Ingrid U Scott
Journal:  Curr Ophthalmol Rep       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.